Notch activation inhibits AML growth and survival: a potential therapeutic approach
Open accessThe DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
Although aberrant Notch activation contributes to leukemogenesis in T cells, its role in acute myelogenous leukemia (AML) remains unclear. Here, we report that human AML samples have robust expression of Notch receptors; however, Notch receptor activation and expression of downstream Notch targets are remarkably low, suggesting that Notch is present but not constitutively activated in human AML. The functional role of these Notch receptors in AML is not known. Induced activation through any of the Notch receptors (Notch1–4), or through the Notch target Hairy/Enhancer of Split 1 (HES1), consistently leads to AML growth arrest and caspase-dependent apoptosis, which are associated with B cell lymphoma 2 (BCL2) loss and enhanced p53/p21 expression. These effects were dependent on the HES1 repressor domain and were rescued through reexpression of BCL2. Importantly, activated Notch1, Notch2, and HES1 all led to inhibited AML growth in vivo, and Notch inhibition via dnMAML enhanced proliferation in vivo, thus revealing the physiological inhibition of AML growth in vivo in response to Notch signaling. As a novel therapeutic approach, we used a Notch agonist peptide that led to significant apoptosis in AML patient samples. In conclusion, we report consistent Notch-mediated growth arrest and apoptosis in human AML, and propose the development of Notch agonists as a potential therapeutic approach in AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, Notch signaling functions as a tumor suppressor in the malignancies of myeloid origin, such as acute myelogenous leukemia and chronic myeloid leukemia [138, 139].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [138]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,715 · cited 2×
“…independent of which activated receptor was expressed, suggesting that a common downstream target expression had no effect on T-ALL cell line growth, whereas Notch inhibition via expression of dnMAML inhibited the growth of the MOLT4 and SUPT1 T-ALL lines, as expected (Weng et al., 2003, 2004).”
BackgroundResultProduction of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266 · cited 1×
“The production of retroviral supernatant and transduction of each cell line was performed following previously established methods (Pear et al., 1993).”
MethodEllisen, L. W., Bird, J., West, D. C., Soreng, A. L., Reynolds, T. C., Smith, S. D., & Sklar, J. (1991) · Cell · doi:10.1016/0092-8674(91)90111-b · Cited by 1,696
Notch1 Expression in Early Lymphopoiesis Influences B versus T Lineage Determination
Pui, J. C., Allman, D., Xu, L., DeRocco, S., Karnell, F. G., Bakkour, S., Lee, J. Y., Kadesch, T., Hardy, R. R., Aster, J. C., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80105-3 · Cited by 949
Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G. B., & Kornblau, S. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0334 · Cited by 718 · cited 1×
“We probed a validated reversephase protein lysate array (RPPA) containing duplicate dilutions of total cell lysates from 560 AML patient samples, 10 normal CD34-selected controls, and 21 normal peripheral blood mononuclear cell controls (Tibes et al., 2006; Kornblau and Coombes, 2011).”
MethodSelf-citationPucci, B., Kasten, M., & Giordano, A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900101 · Cited by 652
Saito, T., Chiba, S., Ichikawa, M., Kunisato, A., Asai, T., Shimizu, K., Yamaguchi, T., Yamamoto, G., Seo, S., Kumano, K., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00111-0 · Cited by 561
Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
Harrison, H., Farnie, G., Howell, S. J., Rock, R. E., Stylianou, S., Brennan, K. R., Bundred, N. J., & Clarke, R. B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1681 · Cited by 543 · cited 1×
“Interestingly, AML and normal CD34+ cells expressed similar levels of Notch receptors 1–3, but AML samples expressed significantly higher Notch4, the Notch receptor classically associated with vascular endothelium (Wu et al., 2005) and breast cancer (Harrison et al., 2010).”
Cited by
Notch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,114
Clara, J. A., Monge, C., Yang, Y., & Takebe, N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0293-2 · Cited by 752
Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts
Kode, A., Manavalan, J. S., Mosialou, I., Bhagat, G., Rathinam, C. V., Luo, N., Khiabanian, H., Lee, A., Murty, V. V., Friedman, R., et al. (2014) · Nature · doi:10.1038/nature12883 · Cited by 532
Therapeutic modulation of Notch signalling — are we there yet?
Andersson, E. R., & Lendahl, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4252 · Cited by 457
From Fly Wings to Targeted Cancer Therapies: A Centennial for Notch Signaling
Ntziachristos, P., Lim, J. S., Sage, J., & Aifantis, I. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.018 · Cited by 374
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“However, Notch signaling functions as a tumor suppressor in the malignancies of myeloid origin, such as acute myelogenous leukemia and chronic myeloid leukemia [138, 139].”
BackgroundNotch signaling: switching an oncogene to a tumor suppressor
Lobry, C., Oh, P., Mansour, M. R., Look, A. T., & Aifantis, I. (2014) · Blood · doi:10.1182/blood-2013-08-355818 · Cited by 249
“Two different studies published this year by our group and Zweidler-McKay’s group addressed the role of Notch signaling in AML.(106,107) Both studies used whole-genome expression data from AML patients to show that the Notch signaling pathway is silenced, as revealed by absence of expression of knownNotch target genes…”
BackgroundResultInfluentialThe Notch ligand Jagged1 as a target for anti-tumor therapy
Li, D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00254 · Cited by 187
“JAG1 stimulation was also found to suppress AML cell line growth (108), and high JAG1 surface levels in leukemia cells was proposed as an independent favorable prognostic factor in AML patients (109).”
BackgroundInfluentialTargeting acute myeloid leukemia stem cell signaling by natural products
Siveen, K. S., Uddin, S., & Mohammad, R. M. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0571-x · Cited by 162
“Human AML samples have extremely low levels of activated Notch receptor and expression of downstream targets, even with a robust expression of Notch receptors, suggesting that Notch is not constitutively activated [62].”
Prokocimer, M., Molchadsky, A., & Rotter, V. (2017) · Blood · doi:10.1182/blood-2017-02-763086 · Cited by 162
“Indeed, Notch agonistswere shown to enhance p53 expression along with BCL2 downregulation and growth inhibition of AML cells.(93)”
BackgroundZheng, Y., de la Cruz, C. C., Sayles, L. C., Alleyne-Chin, C., Vaka, D., Knaak, T. D., Bigos, M., Xu, Y., Hoang, C. D., Shrager, J. B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.021 · Cited by 154
“Indeed, recent studies demonstrate low intracellular Notch signaling in acute myeloid leukemia (AML) cells despite high expression of Notch2 at the cell surface (Kannan et al., 2013; Lobry et al., 2013).”
Targeting cell cycle regulators in hematologic malignancies
Aleem, E., & Arceci, R. J. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00016 · Cited by 120
“This phosphorylation disrupts EZH2 binding with the other PRC2 components SUZ12 and EED, and inhibits EZH2 methyltransferase activity, resulting in inhibition of cancer-cell invasion as well (Wei et al., 2011).”
BackgroundNotch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia
Kamga, P. T., Bassi, G., Cassaro, A., Midolo, M., Trapani, M. D., Gatti, A., Carusone, R., Resci, F., Perbellini, O., Gottardi, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7964 · Cited by 98
“In myeloid counterpart the role of Notch remains controversial: some authors described Notch expression and activation in AML samples and AML cell lines, but the pathway was slightly activated, as demonstrated by the low expression level of Notch target genes [11-13].”
BackgroundResultInfluentialConnolly, K., Manders, P., Earls, P., & Epstein, R. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.08.005 · Cited by 79
“Recent deployment of synthetic Notch ligands and proapoptotic Notch agonist peptides [67] with antitumor activity highlights the relevance of this pathway for therapeutic targeting.”
BackgroundThe strategies to cure cancer patients by eradicating cancer stem-like cells
Mai, Y., Su, J., Yang, C., Xia, C., & Fu, L. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01867-y · Cited by 82
“Aberrant activation of Notch signaling promotes the development of most solid tumors but suppresses myeloid malignancies [77, 78].”
BackgroundNormal Hematopoiesis Is a Balancing Act of Self-Renewal and Regeneration
Olson, O. C., Kang, Y.-A., & Passegué, E. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035519 · Cited by 76
Mitochondrial dependency in progression of acute myeloid leukemia
Basak, N. P., & Banerjee, S. (2015) · Mitochondrion · doi:10.1016/j.mito.2015.01.006 · Cited by 85
Notch signaling: its roles and therapeutic potential in hematological malignancies
Gu, Y., Masiero, M., & Banham, A. H. (2016) · Oncotarget · doi:10.18632/oncotarget.7772 · Cited by 78
“Interestingly, in the case of acute myeloid leukemia (AML) the role of the Notch pathway is not well understood, with different reports describe contrasting results.”
BackgroundInfluentialFelices, M., Ankarlo, D., Lenvik, T. R., Nelson, H. H., Blazar, B. R., Verneris, M. R., & Miller, J. S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400534 · Cited by 74
“targeting the Notch pathway in the acute myeloid leukemia setting is that Notch activation has recently been shown to directly inhibit acute myeloid leukemia growth and survival (56).”
Mechanisms in Endocrinology: Notch signaling in skeletal health and disease
Zanotti, S., & CANALIS, E. M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0115 · Cited by 66
Pleyer, L., Valent, P., & Greil, R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071009 · Cited by 65
Cell signaling pathways as molecular targets to eliminate AML stem cells
Rodrigues, A. C., Costa, R. G. A., Silva, S. L. R., Dias, I. R. S. B., Dias, R. B., & Bezerra, D. P. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103277 · Cited by 64
Transcription Factor RBPJ as a Molecular Switch in Regulating the Notch Response
Giaimo, B. D., Gagliani, E. K., Kovall, R. A., & Borggrefe, T. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55031-8_2 · Cited by 63
The Role of Notch and Wnt Signaling in MSC Communication in Normal and Leukemic Bone Marrow Niche
Takam Kamga, P., Bazzoni, R., Dal Collo, G., Cassaro, A., Tanasi, I., Russignan, A., Tecchio, C., & Krampera, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.599276 · Cited by 53
Alteration of Mitochondrial Proteome Due to Activation of Notch1 Signaling Pathway
Basak, N. P., Roy, A., & Banerjee, S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.519405 · Cited by 55
“K562 cells express Notch1 receptors, but the pathway is not activated (17).”
BackgroundAdamia, S., Bar‐Natan, M., Haibe‐Kains, B., Pilarski, P. M., Bach, C., Pevzner, S. J., Calimeri, T., Avet‐Loiseau, H., Lodé, L., Verselis, S. J., et al. (2014) · Blood · doi:10.1182/blood-2013-02-481507 · Cited by 62
“FLT3 is already known as a frequently mutated oncogene in AML, whereas the role ofNOTCH2 in this disease is not well understood, although decreased NOTCH2 expression has been linked to AML in 2 reports.(35,36) Cloning and sequencing analysis identified several aberrant splice variants of NOTCH2 and FLT3 that resulted…”
BackgroundInfluence of Bone Marrow Microenvironment on Leukemic Stem Cells
Agarwal, P., & Bhatia, R. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.007 · Cited by 57
Lindqvist, C. M., Lundmark, A., Nordlund, J., Freyhult, E., Ekman, D. S., Almlöf, J. C., Raine, A., Övernäs, E., Abrahamsson, J., Frost, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11773 · Cited by 50
“While the majority of somatic mutations in NOTCH1 in T-ALL are activating and result in aberrant continued signaling [21], a tumor suppressor role of the Notch pathway has been shown in acute myeloid leukemia (AML) [22, 23].”
BackgroundThe NOTCH signaling pathway in normal and malignant blood cell production
Suresh, S., & Irvine, A. E. (2015) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-015-0271-0 · Cited by 50
“…study CD34+ bone marrow cells from AML patients had NOTCH1 and NOTCH2 expression similar to the normal donor samples, however the levels of NOTCH targets HES1 and DELTEX1 were lower in AML cells indicating reduced NOTCH signalling despite the expression of NOTCH receptors (Kannan et al. 2013).”
Oncogenic Notch signaling in T-cell and B-cell lymphoproliferative disorders
Chiang, M. Y., Radojčić, V., & Maillard, I. P. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000254 · Cited by 47
Zhdanovskaya, N., Firrincieli, M., Lazzari, S., Pace, E., Rossi, P. S., Felli, M. P., Talora, C., Screpanti, I., & Palermo, R. (2021) · Cancers · doi:10.3390/cancers13205106 · Cited by 47
Understanding the Role of Notch in Osteosarcoma
McManus, M. M., Weiss, K. R., & Hughes, D. P. M. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_4 · Cited by 51
Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy
Kannan, S., Irwin, M. E., Herbrich, S. M., Cheng, T., Patterson, L. L., Aitken, M. J. L., Bhalla, K. N., You, M. J., Konopleva, M. Y., Zweidler‐McKay, P. A., et al. (2022) · Antioxidants · doi:10.3390/antiox11040717 · Cited by 44
“5 × 106 MOLM13 or MOLM13-TKIR cells as described previously [17,19].”
MethodSelf-citationAithal, M. G. S., & Rajeswari, N. (2019) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2019.7.e21 · Cited by 48
“Induced overexpression of HES1 in vitro and in vivo led to growth arrest and apoptosis in acute myeloid leukaemia and hepatocellular carcinoma supporting the tumour suppressor role of HES1 in these cancers [31-33].”
BackgroundHes1 suppresses acute myeloid leukemia development through FLT3 repression
Kato, T., Sakata‐Yanagimoto, M., Nishikii, H., Ueno, M., Miyake, Y., Yokoyama, Y., Asabe, Y., Kamada, Y., Muto, H., Obara, N., et al. (2014) · Leukemia · doi:10.1038/leu.2014.281 · Cited by 44
Bone marrow microenvironment: The guardian of leukemia stem cells
Houshmand, M., Blanco, T. M., Circosta, P., Yazdi, N., Kazemi, A., Saglio, G. N., & Zarif, M. N. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i8.476 · Cited by 52
Context-dependent roles for lymphotoxin-β receptor signaling in cancer development
Fernandes, M. T., Dejardin, E., & dos Santos, N. R. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.02.005 · Cited by 52
Kamga, P. T., Collo, G. D., Midolo, M., Adamo, A., Delfino, P., Mercuri, A., Cesaro, S., Mimiola, E., Bonifacio, M., Andreini, A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1617 · Cited by 43
“Lobry and colleagues (22) and Kanan and colleagues (23) previously reported that the presence ofNotch receptors and ligands does not always correlate with the activation of the pathway.”
BackgroundTQ inhibits hepatocellular carcinoma growthin vitroandin vivovia repression of Notch signaling
Ke, X., Zhao, Y., Lu, X., Wang, Z., Liu, Y., Ren, M., Lu, G., Zhang, D., Sun, Z., Xu, Z., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5362 · Cited by 40
Yue, Y., Zhou, K., Li, J., Jiang, S., Li, C., & Men, H.-T. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s165144 · Cited by 40
The emerging roles of Notch signaling in leukemia and stem cells
Liu, N., Zhang, J., & Ji, C. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-23 · Cited by 39
“have found that all four Notch homologues and Hes1 were sufficient to inhibit the growth and induced caspase-dependent apoptosis of AML, which were associated with B cell lymphoma 2 (BCL2) loss and enhanced p53/p21 expression [45].”
BackgroundResultInfluentialDeregulated Notch and Wnt signaling activates early-stage myeloid regeneration pathways in leukemia
Kang, Y.-A., Pietras, E. M., & Passegue, E. A. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190787 · Cited by 45
Liu, T., Zhang, Z., Yu, C., Zeng, C., Xu, X., Wu, G., Huang, Z., & Li, W. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14031 · Cited by 41
“Some reports suggest that activation of Notch signalling in AML cells led to growth arrest, apoptosis and differentiation (Chadwick et al., 2008; Roy et al., 2012; Kannan et al., 2013; Lobry et al., 2013), whereas some others indicate the reverse effects (Mercher et al., 2009).”
BackgroundResultSoluble and multivalent Jag1 DNA origami nanopatterns activate Notch without pulling force
Smyrlaki, I., Fördős, F., Rocamonde-Lago, I., Wang, Y., Shen, B., Lentini, A., Luca, V. C., Reinius, B., Teixeira, A. I., & Högberg, B. (2024) · Nature Communications · doi:10.1038/s41467-023-44059-4 · Cited by 40
“Targeted Notch activation can also be bene fi cial in several other diseases: it inhibits acute myeloblastic leukemia growth and increases survival 47 , it is suggested as a treatment for Notch ligand loss of function diseases like Alagille Syndrome and for regenerative medicine 48,49 .”
BackgroundEffects of Notch glycosylation on health and diseases
Urata, Y., & Takeuchi, H. (2019) · Development Growth & Differentiation · doi:10.1111/dgd.12643 · Cited by 39
“Inactivation of NOTCH1 promotes cell proliferation in AML and squamous cell carcinoma (SCC; Brooks et al., 2014; Kannan et al., 2013; Lobry et al., 2013; Wang et al., 2011).”
BackgroundMoreira, M. Â. M., Bagni, C., de Pinho, M. B., McCormick, T. M., Mota, M. D. S., Pinto-Silva, F. E., Daflon-Yunes, N., & Rumjanek, V. M. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.06.001 · Cited by 42
NOTCH Mutations: Multiple Faces in Human Malignancies
Mao, L. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0063 · Cited by 35
“In acute myeloid leukemia (AML), activation of the NOTCH signaling pathway can result in a disease remission (17).”
BackgroundSmall molecule activation of NOTCH signaling inhibits acute myeloid leukemia
Qi, Y., Jiang, J., Zhan, G., Yan, W., Huang, L., Hu, Y., Su, H., Tong, Q., Yue, M., Li, H., et al. (2016) · Scientific Reports · doi:10.1038/srep26510 · Cited by 37
McCarter, A. C., Wang, Q., & Chiang, M. Y. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-89512-3_18 · Cited by 43
Anti-leukemic effects of the V-ATPase inhibitor Archazolid A
Zhang, S., Schneider, L. S., Vick, B., Grunert, M., Jeremias, I., Menche, D., Müller, R., Vollmar, A. M., & Liebl, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6180 · Cited by 35
“On the other hand, activation of Notch or of the Notch downstream target Hes1 inhibits leukemia development, growth and survival [7-9].”
BackgroundSignaling Pathways in Leukemic Stem Cells
Gurska, L. M., Ames, K. T., & Gritsman, K. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7342-8_1 · Cited by 38
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia
Kamga, P. T., Collo, G. D., Resci, F., Bazzoni, R., Mercuri, A., Quaglia, F. M., Tanasi, I., Delfino, P., Visco, C., Bonifacio, M., et al. (2019) · Cancers · doi:10.3390/cancers11121958 · Cited by 33
Deng, G., Ma, L., Qi, M., Ju, X., Jiang, K., Jiang, P., & Yu, Z. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1946-x · Cited by 35
The role of notch signaling in bone marrow niche
Azizidoost, S., Bavarsad, M. S., Bavarsad, M. S., Shahrabi, S., Jaseb, K., Rahim, F., Shahjahani, M., Saba, F., Ghorbani, M., & Saki, N. (2014) · Hematology · doi:10.1179/1607845414y.0000000167 · Cited by 31
Heidel, F. H., Arreba-Tutusaus, P., Armstrong, S. A., & Fischer, T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1436 · Cited by 30
“This indicated for the first time a crucial role inmaintenance of an immature state (19).”
Tan, M., Zhang, Q., Yuan, X., Chen, Y., & Wu, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1295-8 · Cited by 32
Nasser, F., Moussa, N., Helmy, M. W., & Haroun, M. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01988-x · Cited by 29
Vujković, M., Attiyeh, E. F., Ries, R. E., Goodman, E. K., Ding, Y., Kavčič, M., Alonzo, T. A., Wang, Y.-C., Gerbing, R. B., Sung, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-772384 · Cited by 29
“Two studies showed that DLL4 and NOTCH1 expression was significantly higher in patients with AML than in controls, indicating that activation of NOTCH signaling may promote AML development and be associated with an unfavorable prognosis.(28,29) Also at this breakpoint is MLLT4 (AF6), the partner of MLL in t(6;11)(q27;…”
BackgroundPathway perturbations in signaling networks: Linking genotype to phenotype
Li, Y., McGrail, D. J., Latysheva, N. S., Yi, S. S., Babu, M. M., & Sahni, N. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.05.001 · Cited by 30
“For example, activation of Notch signaling pathway was reported in a remission of acute myeloid leukemia [65].”
BackgroundThe Challenge of Targeting Notch in Hematologic Malignancies
Tejada, F. N. H., Silva, J. R. G., & Zweidler‐McKay, P. A. (2014) · Frontiers in Pediatrics · doi:10.3389/fped.2014.00054 · Cited by 30
Self-citationTian, C., You, M. J., Yu, Y., Zhu, L., Zheng, G., & Zhang, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-4581-x · Cited by 27
Pakkiriswami, S., Couto, A., Nagarajan, U., & Γεωργίου, Μ. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00037 · Cited by 29
“In hematopoietic cancers, for example, T cell active lymphoblastic leukemia (T-ALL), Notch has an oncogenic role (59, 60), while in acute myeloid leukemia (AML), it has a tumor-suppressive role (61, 62).”
BackgroundTargeting self-renewal pathways in myeloid malignancies
Sands, W. A., Copland, M., & Wheadon, H. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-33 · Cited by 33
“Consistent with this is the finding that Notch signaling is down-regulated in AML, and activation of it, targets LSCs, inducing apoptosis, and promoting differentiation to dendritic cells and macrophages [59,60].”
BackgroundJagged1 DNA Copy Number Variation Is Associated with Poor Outcome in Liver Cancer
Kawaguchi, K., Honda, M., Yamashita, T., Okada, H., Shirasaki, T., Nishikawa, M., Nio, K., Arai, K., Sakai, Y., Yamashita, T., et al. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.04.011 · Cited by 30
Bill, M., Pathmanathan, A., Karunasiri, M. S., Shen, C., Burke, M. H., Ranganathan, P., Papaioannou, D., Zitzer, N. C., Snyder, K. J., LaRocco, A. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2479 · Cited by 26
“Several groups have shown that NOTCH signaling is silenced in AML and that reactivation of NOTCH signaling results in blast differentiation and disease elimination (16, 17).”
BackgroundMethodTargeting Notch Trafficking and Processing in Cancers
Pagliaro, L., Sorrentino, C., & Roti, G. (2020) · Cells · doi:10.3390/cells9102212 · Cited by 25
“Most pieces of evidence suggest that Notch negatively regulates disease progression [160,161] through a cross-talk with the tumor microenvironment.”
BackgroundDongdong, Z., Jin, Y., Yang, T., Yang, Q., Wu, B., Chen, Y., Luo, Z., Li, L., Liu, Y., Xu, A., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01396 · Cited by 24
Tohda, S. (2014) · PubMed · Cited by 23
Yu, G., Chen, Y., Hu, Y., Zhou, Y., Ding, X., & Zhou, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1010639 · Cited by 26
“The loss of TLE1/ TLE4 disrupts the TLE/HES1/HDAC complex, which otherwise inhibits AML growth by increasing p53/p21 and decreasing Bcl-2 expression (Kannan et al., 2013).”
BackgroundHES1 activation suppresses proliferation of leukemia cells in acute myeloid leukemia
Tian, C., Yu, Y., Jia, Y., Zhu, L., & Zhang, Y. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2413-0 · Cited by 21
“Similarly, Kannan and Lobry reported that Notch was silenced in AML [6, 7].”
BackgroundRequirement for Ssbp2 in Hematopoietic Stem Cell Maintenance and Stress Response
Li, J., KURASAWA, Y., Wang, Y., Clise-Dwyer, K., Klumpp, S. A., Hong, L., Tailor, R. C., Raymond, A. C., Estrov, Z. E., Brandt, S. J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1300337 · Cited by 20
“Finally, because accumulating evidence suggests a myeloid suppressor role for NOTCH1 (24, 25), we evaluated the expression of NOTCH1 and SSBP2 from data obtained from the Cancer Genome Atlas”
BackgroundMethodSelf-citationNOTCH knockdown affects the proliferation and mTOR signaling of leukemia cells.
Okuhashi, Y., Itoh, M., Nara, N., & Tohda, S. (2013) · PubMed · Cited by 20
Influence of Long Non-Coding RNA in the Regulation of Cancer Stem Cell Signaling Pathways
Sonawala, K., Ramalingam, S., & Sellamuthu, I. (2022) · Cells · doi:10.3390/cells11213492 · Cited by 19
Hayakawa, S., 小出, 亮., Hinou, H., & Nishimura, S. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01284 · Cited by 22
NOTCH-1 Gene Mutations Influence Survival in Acute Myeloid Leukemia Patients
Aref, S., Rizk, R., -Agder, M. E., Fakhry, W., Elzaafarany, M., & Sabry, M. A. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.7.1987 · Cited by 18
“Association between inferior outcome and NOTCH-1 mutations or hyperexpression was also noticed by many authors in human samples (Kannan et al., 2013; Sliwa et al., 2014; Lutherborrow et al., 2014; Lobry et al., 2018; Czemerska et al., 2015; Kamga et al., 2018).”
BackgroundResultInfluentialLáinez‐González, D., Serrano‐López, J., & Alonso‐Domínguez, J. M. (2022) · Cancers · doi:10.3390/cancers14061459 · Cited by 20
“Additionally, the authors showed that the activation of NOTCH1, NOTCH2, and HES1 led to reduced AML growth in vivo [46].”
BackgroundResultInfluentialChiou, H.-Y. C., Liu, S., Lin, C.-H., & Lee, E. H. Y. (2014) · Journal of Biomedical Science · doi:10.1186/1423-0127-21-53 · Cited by 18
“But there are also reports showing that Hes-1 plays a proapoptotic role [56,57].”
BackgroundFei, C., Guo, J., Zhao, Y., Gu, S., Zhao, S., Li, X., & Chang, C. (2015) · Europe PMC (PubMed Central) · Cited by 20
Kong, G., You, X., Wen, Z. H., Chang, Y., Qian, S., Ranheim, E. A., Letson, C. T., Zhang, X., Zhou, Y., Liu, Y., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0248-0 · Cited by 21
Novel Drug Therapies in Myeloid Leukemia: a Patent Review
Horne, G. A., Kinstrie, R., & Copland, M. (2015) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.15.3 · Cited by 18
Dawes, W. J., Zhang, X., Fancy, S. P. J., Rowitch, D. H., & Marino, S. (2016) · Developmental Neuroscience · doi:10.1159/000455839 · Cited by 17
Bhattacharjee, R., Ghosh, S., Nath, A., Basu, A., Biswas, O., Patil, C. R., & Kundu, C. N. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103753 · Cited by 18
Horne, G. A., & Copland, M. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1303477 · Cited by 15
Kannan, S., Aitken, M. J. L., Herbrich, S. M., Golfman, L. S., Hall, M. G., Mak, D. H. F., Burks, J. K., Song, G., Konopleva, M. Y., Mullighan, C. G., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0706 · Cited by 14
“Fifty micrograms of protein were loaded for Western analyses as described previously (26).”
MethodSelf-citationPut in a “Ca2+ll” to Acute Myeloid Leukemia
Lewuillon, C., Laguillaumie, M.-O., Quesnel, B., Idziorek, T., Touil, Y. S., & Lemonnier, L. (2022) · Cells · doi:10.3390/cells11030543 · Cited by 18
“Other studies have shown, however, that Notch activation can inhibit AML growth and also alter AML-initiating cell compartments [31,32].”
BackgroundCzemerska, M., Pluta, A., Szmigielska‐Kapłon, A., Wawrzyniak, E., Cebula‐Obrzut, B., Mędra, A., Smolewski, P., Robak, T., & Wierzbowska, A. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.917638 · Cited by 13
Park, J., Joung, J.-Y., Hwang, J., Hong, D., Park, W. S., Lee, S.-J., & Lee, K. H. (2017) · Anticancer Research · doi:10.21873/anticanres.11500 · Cited by 13
Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia
Lordo, M. R., Scoville, S. D., Goel, A., Yu, J., Freud, A. G., Caligiuri, M. A., & Mundy-Bosse, B. L. (2021) · Cancers · doi:10.3390/cancers13020320 · Cited by 13
The Role of Innate Lymphoid Cells in Cancer Development and Immunotherapy
Sugimura, R., & Wang, C. Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.803563 · Cited by 13
Lysosome-mediated chemoresistance in acute myeloid leukemia
Cuesta‐Casanovas, L., Delgado-Martínez, J., Cornet-Masana, J. M., Carbo, J. M. C. I., Clément-Demange, L., & Risueño, R. M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.122 · Cited by 15
Chen, J., Gao, X., Yang, L., Fu, W., Liang, L., Li, J., Hu, B., Sun, Z.-J., Huang, S., Zhang, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep26003 · Cited by 14
Laranjeira, A. B. A., & Yang, S. X. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1236785 · Cited by 14
Rosales, M., Rodríguez‐Ulloa, A., Pérez, G. V., Besada, V., Soto, T., Ramos, Y., González, L. J., Zettl, K., Wiśniewski, J. R., Yang, K., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.834814 · Cited by 10
“However, specifically in AML, accumulating pieces of evidence suggest that Notch signaling pathway has a tumor suppressor role (Kannan et al., 2013; Lobry et al., 2013).”
BackgroundOno, M., Takimoto, R., Osuga, T., Okagawa, Y., Hirakawa, M., Yoshida, M., Arihara, Y., Uemura, N., Hayasaka, N., Miura, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9558 · Cited by 10
“Recently, it has been shown that Notch mediates growth arrest and apoptosis in AML cells via activation of Hairy/Enhancer of Split 1 (HES1), suggesting the development of Notch agonists as a new therapy [24].”
BackgroundVacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia
Aasebø, E., Bartaula-Brevik, S., Hernandez-Valladares, M., & Bruserud, Ø. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1407239 · Cited by 10
“Two recent studies described a tumor suppressive effect of Notch activation in human AML cells with cell cycle arrest, growth inhibition, and induction of apoptosis [52,53].”
BackgroundReimels, T. A., & Pfleger, C. M. (2015) · Journal of Cell Science · doi:10.1242/jcs.174433 · Cited by 10
“However, there are conflicting reports on the role of Notch signaling in AMLs, which might reflect unresolved heterogeneity within this cancer type (Tohda and Nara, 2001; Asha et al., 2003; Tohda et al., 2005; Kannan et al., 2013; Zhang et al., 2013).”
BackgroundKruk, A., Ociepa, T., Urasiński, T., Grabarek, J., & Urasińska, E. (2015) · Polish Journal of Pathology · doi:10.5114/pjp.2015.54957 · Cited by 11
“reported that Notch 1-related transcription factors stimulate higher expression of PARP-1 messenger RNA and thus induce apoptosis in B-ALL cell lines, an effect not seen in T-ALL cell lines [20].”
BackgroundGene networks in basal cell carcinoma of the eyelid, analyzed using gene expression profiling
Yunoki, T., Tabuchi, Y., Hirano, T., Miwa, S., Imura, J., & Hayashi, A. (2018) · Oncology Letters · doi:10.3892/ol.2018.9484 · Cited by 12
“The cancer cell growth gene network consisted of nine genes, that is, AR (25), BCL2 (26), IGFBP5 (27), CXCL12 (28), ERBB3 (29), MMP2 (30), PDGFRA (31), PLAT (32) and PSCA (33), which have been found to be associated with the cell growth of various cancers, such as renal cell carcinoma,…”
The role of SF3B1 and NOTCH1 in the pathogenesis of leukemia
Abolhasani, S., Hejazian, S. S., Karpisheh, V., Khodakarami, A., Mohammadi, H., Navashenaq, J. G., Hojjat‐Farsangi, M., & Jadidi‐Niaragh, F. (2022) · IUBMB Life · doi:10.1002/iub.2660 · Cited by 12
“However, NOTCH1 signaling activity and expression of its target genes are significantly reduced in AML, which is in contrast to the enhanced expression of NOTCH1 protein in these cell lines.(199,200) In this context, the authors demonstrated that reactivating NOTCH1 in human and mouse AML cells using inducible express…”
Inside the Battle Against Acute Myeloid Leukemia: Biology, Breakthroughs, and Hope
Bao, J., Freund, O., Sund, L., & Du, W. (2026) · Cells · doi:10.3390/cells15040338 · Cited by 15
“Functionally, NOTCH inhibition promotes expansion of multipotent progenitors, whereas enforced activation of NOTCH signaling restricts AML growth and LSC maintenance, supporting a tumor-suppressive role for NOTCH in AML [159,160].”
Metadata
- Authors
- Kannan, S., Sutphin, R. M., Hall, M. G., Golfman, L. S., Fang, W., Nolo, R. M., Akers, L. J., Hammitt, R. A., McMurray, J. S., Kornblau, S. M., Melnick, A. M., Figueroa, M. E., & Zweidler-McKay, P. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Department of Pediatric Hematology/Oncology, M.D. Anderson Cancer Center Orlando, Orlando, FL 32806 4
- Cook Children's Medical Center (US)
- Sigma Genosys (United States) (US)
- Weill Cornell Medicine (US)
- Department of Pathology, University of Michigan Health System, Ann Arbor, MI 48109 8
- Division of Pediatrics 1 , 2 , and 3
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-01-28
- Volume
- 210
- Issue
- 2
- Pages
- 321-337
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3570106
- OpenAlex
- W2113096952
- Cited by
- 152
- References
- 59
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 16 · 2021: 8 · 2020: 8 · 2019: 12 · 2018: 12 · 2017: 8 · 2016: 15 · 2015: 18 · 2014: 20 · 2013: 10
- FWCI
- 15.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA138816, P30CA016672)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- Notch signaling, acute myeloid leukemia, Notch1, Notch2, Notch3, Notch4, Hes1, apoptosis, Bcl-2, therapeutic target
- MeSH terms
- Transcription Factor HES-1, Adolescent, Animals, Cell Survival, Child, DNA-Binding Proteins, Humans, Infant, Mutation, RNA, Messenger, RNA, Neoplasm, Transcription Factors, Signal Transduction, Leukemia, Myeloid, Acute, Gene Expression, Tumor Suppressor Protein p53, Mice, SCID, Mice, Inbred NOD, Apoptosis, Mice, Knockout, Homeodomain Proteins, Proto-Oncogene Proteins c-bcl-2, Cell Line, Tumor, Cell Proliferation, Mice, Basic Helix-Loop-Helix Proteins, Receptors, Notch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.